Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)

Mizuho Securities reiterated a Buy rating for Vaxcyte (PCVX) on June 18 and set a price target of $163. The company’s shares closed last Thursday at $51.44. The analyst, Salim Syed, covers the Healthcare sector, focusing on companies such as Century Therapeutics, Atara Biotherapeutics, and Assembly Biosciences. TipRanks data cited in the article shows Syed with an average return of -1.0% and a 42.91% success rate on recommended stocks.

The article notes that analyst consensus remains a Strong Buy, with an average price target of $116, representing 125.51% upside from current levels. It also references a June 3 report from Guggenheim, which maintained a Buy rating with the same $116 price target. On fundamentals, Vaxcyte’s latest earnings release for the quarter ended March 31 showed a quarterly GAAP net loss of $320.62 million. In the prior year, the GAAP net loss was $140.72 million, indicating a wider loss year-over-year.